W. Joseph Herring - Concepedia

Author

W. Joseph Herring

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

W Herring, W Joseph Herring, W. Herring, W. J. Herring, W. Joseph Herring, W.J. Herring, Wilbur Herring, William Herring, William J. Herring, William Joseph Herring

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Henry Ford Hospital Duke University Johns Hopkins Medicine Johns Hopkins University

About

W. Joseph Herring is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, sleep, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	15	1.8K
2	Social Sciences	2	2	271
3	Engineering	1	1	18
4	Natural Sciences	1	1	213
5	Allergy	1	1	29

W. Joseph Herring

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial David Michelson, Ellen Snyder, Erin M. Paradis, The Lancet Neurology Sleep MedicineSleep1-Year TreatmentPlacebo-controlled TrialPharmacotherapy	2014	503
Orexin receptor antagonism for treatment of insomnia W. Joseph Herring, Ellen Snyder, Kerry Budd, Neurology	2012	317
Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials W. Joseph Herring, Kathryn M. Connor, Neely Ivgy-May, Biological Psychiatry Sleep DisordersSleepSleep DisorderPsychiatryPharmacotherapy	2014	284
NMDA But Not Non-NMDA Excitotoxicity is Mediated by Poly(ADP-Ribose) Polymerase Allen S. Mandir, Marc F. Poitras, Adam R. Berliner, Journal of Neuroscience Molecular BiologyCell DeathEnzymatic ModificationOxidative StressBrain Injury	2000	213
A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder Lobna Ibrahim, Nancy Diazgranados, Libby Jolkovsky, Journal of Clinical Psychopharmacology Psychotropic MedicationPsychopharmacologyPharmacotherapyMental HealthSocial Sciences	2012	212
Nuclear Targeting of Mutant Huntingtin Increases Toxicity Matthew F. Peters, Frederick C. Nucifora, Jonathan Kushi, Molecular and Cellular Neuroscience Knockout MouseNeurodegenerative DiseasesDevelopmental BiologyNuclear Localization SignalMolecular Biology	1999	192
Dynamic regulation of neuronal NO synthase transcription by calcium influx through a CREB family transcription factor-dependent mechanism Masayuki Sasaki, Mirella Gonzalez‐Zulueta, Hui Huang, Proceedings of the National Academy of Sciences	2000	176
Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial W. Joseph Herring, Paulette Ceesay, Ellen Snyder, Alzheimer s & Dementia	2020	174
Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis Almira Chabi, Ying Zhang, Saheeda Jackson, Cephalalgia	2014	117
Nuclear Localization of a Non-caspase Truncation Product of Atrophin-1, with an Expanded Polyglutamine Repeat, Increases Cellular Toxicity Frederick C. Nucifora, Lisa Ellerby, Cheryl L. Wellington, Journal of Biological Chemistry	2003	88

Page 1